

## Jubilant Pharmova

8 February 2026

### RESULT UPDATE

Sector: Healthcare	Rating: BUY
CMP: Rs 938	Target Price: Rs 1,325

### Stock Info

Sensex/Nifty	83,580/25,694
Bloomberg	JUBLPHAR IN
Equity shares	159 mn
52-wk High/Low	Rs 1,248/802
Face value	Rs 1
M-Cap	Rs 149bn/USD 1.6bn


### Financial Snapshot (Rs mn)

Y/E March	FY26E	FY27E	FY28E
Sales	81,714	90,613	1,01,496
Gross profit	55,225	61,047	68,615
Gross Margin (%)	67.6%	67.4%	67.6%
EBITDA	12,635	15,392	18,956
Margin (%)	15.5%	17.0%	18.7%
PAT	4,094	6,048	8,435
EPS	25.7	38.0	53.0
DPS(Rs)	3.0	3.0	3.0
ROE(%)	10.0	11.5	15.2
P/E(x)	42.7	28.9	20.7
EV/EBITDA (x)	15.6	12.9	9.3

### Shareholding pattern (%)

	Jun-25	Sep-25	Dec-25
Promoter	47.67	47.67	47.67
FII	17.40	16.56	15.96
DII	9.52	10.53	11.23
Others	25.41	25.24	25.14

### Stock Performance (1-year)



Vishal Manchanda  
vishalmanchanda@systematixgroup.in  
+91 9737437148

Loveleen Bagga, CA  
loveleenbagga@systematixgroup.in  
+91 22 6704 8043

Virti Shah  
virtishah@systematixgroup.in  
+91 22 6704 8099

### Revenue growth inline, transient issues impact margin

Jubilant Pharmova reported revenue at Rs 21,225 mn in 3QFY26, up 16.5% on a YoY basis and up 7.9% on a QoQ basis. Revenue growth was broadly in line with our expectations, but EBTIDA margins were materially lower. EBITDA stood at Rs 2,895 mn in 3QFY26, up 0.7% on a YoY basis and down 15.2% on a QoQ basis. EBITDA margins stood at 13.6% and was lower 214 bps on a YoY basis. EBITDA margins came in lower for three reasons, which in our view are transient and hence a recovery is expected.

- the full cost of the newly commercialized (Line 3) at Spokane sterile CMO facility started hitting the P&L
- The Montreal facility remained shut owing to ongoing remediation and the entire fixed costs related to the facility remained unabsorbed. On top of the typical fixed costs, there were also remediation spends.
- Lower margins (25% during the quarter vs 9M average of 33%) in Allergy immunotherapy business. Lower production during the quarter impacted the margins but should normalize in subsequent quarter.

Going forward, as utilization ramps up at the new line (Line 3), we will see a disproportionate favorable impact on EBITDA. Line 3 is expected to be fully utilized over 3 years and we estimate incremental EBTIDA contribution of Rs. 2500mn to Rs. 3000mn on FY25 base. The key risk to near term earnings revival is Montreal facility which is facing compliance challenges (9 observations at a most recent inspection in November 2025). Based on the 90-day window, before which the USFDA needs to update the facility status post inspection, we expect a decision on Montreal soon. The Montreal facility is important to Jubilant pharmova, as multiple radiopharma products are manufactured here and ongoing challenges can have a negative impact on radiopharma business. We tweak our forecasts on Jubilant Pharmova and roll over to FY28E EPS. We retain our buy rating with a revised PT of Rs 1325 (25x FY28E EPS).

### 3QFY26 earnings highlights

Jubilant Pharmova reported revenue at Rs 21,225 mn in 3QFY26, up 16.5% on a YoY basis and up 7.9% on a QoQ basis. EBITDA stood at Rs 2,895 mn in 3QFY26, up 0.7% on a YoY basis and down 15.2% on a QoQ basis. EBITDA margin for 3QFY26 was 13.6%, down 214 bps on a YoY basis and down 372 bps on a QoQ basis. PAT stood at Rs 558 mn in 3QFY26, down 44.6% on a YoY basis and down 53.5% on a QoQ basis. PAT margin for 3QFY26 was 2.6%, down 290 bps on a YoY basis and down 347 bps on a QoQ basis.

- Radiotherapy at Rs 9,350 mn in 3QFY26, up 11.2% on a YoY basis and up 4.1% on a QoQ basis.
- Allergy Immunotherapy at Rs 1,930 mn in 3QFY26, up 12.9% on a YoY basis and down 0.5% on a QoQ basis.
- CDMO - Sterile Injectables at Rs 4,570 mn in 3QFY26, up 49.3% on a YoY basis and up 16.3% on a QoQ basis.

Investors are advised to refer disclosures made at the end of the research report.

- CRDMO at Rs 2,980 mn in 3QFY26, up 2.1% on a YoY basis and down 0.3% on a QoQ basis.
- Generics at Rs 2,260 mn in 3QFY26, up 13% on a YoY basis and up 35.3% on a QoQ basis.

### Overall Performance

- Quarter reflected a mixed operating performance, where core platforms continued to show strength, while a few segments faced temporary operational and supply-side challenges.

### Sterile Injectables CDMO – Core Growth Engine

- Sterile Injectables CDMO continues to be the key pillar of growth, driven by sustained outsourcing demand from innovator pharma companies.
- The Spokane facility remains central to the strategy, with capacity expansion and debottlenecking progressing as planned.
- There is a robust RFP pipeline, especially from US customers looking to diversify supply chains, which supports confidence in future order inflows.
- Overall visibility here remains strong, making this segment the most consistent contributor to medium-term growth.

### Radiopharma Business

- Radiopharma delivered a stable performance, supported by steady Ruby-Fill installations and improving utilisation levels.
- Growth was partly constrained due to temporary supply challenges in SPECT products, which impacted product availability during the quarter.
- There is an expectation of gradual normalisation, with underlying demand trends remaining intact.

### Radiopharmacy

- Radiopharmacy business showed incremental improvement, aided by PET product traction and ongoing network expansion.
- While margins are still sub-optimal, operating leverage benefits to kick in as volumes improve and utilisation increases across centres.
- The segment remains a steady, long-term play with improving fundamentals.

### Allergy Immunotherapy

- Allergy Immunotherapy continued its recovery phase, with improving demand trends in the US market.
- Margin performance is expected to normalise over time, supported by better scale, pricing actions and operational efficiencies.

### Drug Discovery & CRDMO

- Drug Discovery platform remains strategically important, supported by long-duration contracts and partnerships with global pharma and biotech players.
- While revenue growth in this segment can remain inherently lumpy, the underlying pipeline and engagement levels provide comfort on long-term visibility.

### Operational & One-offs

- The Montreal facility disruption impacted performance during the period; however, corrective measures are largely implemented, and operations are stabilising.
- Focus remains on execution discipline, improving asset utilisation and tighter cost controls across businesses.

### Exhibit 1: Quarterly performance

(Rs mn)	Q3FY25	Q2FY26	Q3FY26	YoY (%)	QoQ(%)	FY24	FY25	YoY (%)
<b>Revenue from operations</b>	<b>18,217</b>	<b>19,664</b>	<b>21,225</b>	<b>16.5</b>	<b>7.9</b>	<b>67,029</b>	<b>72,345</b>	<b>7.9</b>
Raw Material Costs	5,744	5,965	7,163	24.7	20.1	21,407	23,170	8.2
% of revenue	31.5	30.3	33.7	222 bps	341 bps	31.9	32.0	9 bps
Staff costs	5,601	6,362	7,064	26.1	11.0	22,160	22,679	2.3
% of revenue	30.7	32.4	33.3	254 bps	93 bps	33.1	31.3	(171) bps
Other expenses	3,998	3,923	4,103	2.6	4.6	14,454	14,759	2.1
% of revenue	21.9	20.0	19.3	(262) bps	(62) bps	21.6	20.4	(116) bps
<b>EBITDA</b>	<b>2,874</b>	<b>3,414</b>	<b>2,895</b>	<b>0.7</b>	<b>-15.2</b>	<b>9,008</b>	<b>11,737</b>	<b>30.3</b>
<b>EBITDA margin (%)</b>	<b>15.8</b>	<b>17.4</b>	<b>13.6</b>	<b>(214) bps</b>	<b>(372) bps</b>	<b>13.4</b>	<b>16.2</b>	<b>278 bps</b>
Other income	92	98	205	122.8	109.2	687	568	-17.3
Interest costs	556	502	561	0.9	11.8	2,723	2,403	-11.8
Depreciation	913	1,048	1,207	32.2	15.2	3,819	3,686	-3.5
<b>PBT Before Exceptionals</b>	<b>1,497</b>	<b>1,962</b>	<b>1,332</b>	<b>-11.0</b>	<b>-32.1</b>	<b>3,153</b>	<b>6,216</b>	<b>97.1</b>
Exceptional Items	189	58	397	110.1	584.5	1,689	-3,595	-312.8
Share of profit/(loss) of an associate	-3	-1	-1	-66.7	0.0	241	-5	-102.1
<b>PBT</b>	<b>1,305</b>	<b>1,903</b>	<b>934</b>	<b>-28.4</b>	<b>-50.9</b>	<b>1,705</b>	<b>9,806</b>	<b>475.1</b>
Tax	298	704	376	26.2	-46.6	978	1,443	47.5
<b>Tax rate (%)</b>	<b>19.9</b>	<b>35.9</b>	<b>28.2</b>	<b>832 bps</b>	<b>(765) bps</b>	<b>31.0</b>	<b>23.2</b>	<b>(780) bps</b>
<b>PAT</b>	<b>1,007</b>	<b>1,199</b>	<b>558</b>	<b>-44.6</b>	<b>-53.5</b>	<b>727</b>	<b>8,363</b>	<b>1,050.3</b>
<b>PAT Margin (%)</b>	<b>5.5</b>	<b>6.1</b>	<b>2.6</b>	<b>(290) bps</b>	<b>(347) bps</b>	<b>1.1</b>	<b>11.6</b>	<b>1048 bps</b>

Source: Company, Systematix Research

### Exhibit 2: Margin summary

Particulars (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Gross Margin	68.0	70.0	67.6	68.3	68.5	67.5	67.5	69.7	66.3
EBITDA Margin	13.0	15.4	14.5	16.5	15.8	17.9	15.2	17.4	13.6
EBIT Margin	7.4	9.7	9.3	11.3	10.8	13.0	10.1	12.0	8.0
PAT Margin	4.0	-3.5	27.8	5.8	5.5	7.8	5.4	6.1	2.6

Source: Company, Systematix Research

**Exhibit 3: Change in estimates**

Particulars (Rs mn)	New estimates		Old estimates		Change (%)	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Net sales	81,714	90,613	78,240	86,940	4.4	4.2
EBITDA	12,635	15,392	12,990	15,932	(2.7)	(3.4)
Margin (%)	15.5	17.0	16.6	18.3	(114) bps	(134) bps
PAT	4094	6,048	5,632	7,886	(27.3)	(23.3)
Margin (%)	5.1	6.7	7.2	9.1	(219) bps	(240) bps
EPS	25.7	38.0	35.4	49.5	(27.4)	(23.3)

Source: Company, Systematix Research

**Exhibit 4: Actual vs estimates**

Particulars (Rs mn)	Actuals	Systematix	Variance (%)	Consolidated	Variance (%)
Net sales	21,225	20,497	3.6	20,346	4.3
EBITDA	2,895	3,160	(8.4)	3,118	(7.2)
Margin (%)	13.6	15.4	(178) bps	15.3	(169) bps
PAT	558	1,096	(49.1)	1,104	(49.5)
Margin (%)	2.6	5.3	(272) bps	5.4	(280) bps

Source: Company, Systematix Research

## FINANCIALS

### Profit & Loss Statement

YE: Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
<b>Net Revenues</b>	<b>67,029</b>	<b>72,345</b>	<b>81,714</b>	<b>90,613</b>	<b>1,01,496</b>
YoY gr. (%)	7%	8%	13%	11%	12%
Cost of Goods Sold	21,407	23,170	26,489	29,566	32,881
Gross Profit	45,622	49,175	55,225	61,047	68,615
Margin (%)	68%	68%	68%	67%	68%
Employee Cost	22,160	22,679	26,401	27,985	29,664
Other Expenses	14,454	14,759	16,189	17,670	19,995
<b>EBITDA</b>	<b>9,008</b>	<b>11,737</b>	<b>12,635</b>	<b>15,392</b>	<b>18,956</b>
YoY gr. (%)	16%	30%	8%	22%	23%
Margin (%)	13%	16%	15%	17%	19%
Depreciation & Amortization	3,819	3,686	4,443	4,857	5,728
EBIT	5,189	8,051	8,192	10,535	13,228
Margin (%)	8%	11%	10%	12%	13%
Net Interest	2,723	2,403	2,114	1,952	1,979
Other Income	687	568	628	717	796
Exceptional Items	-1,689	3,595	455	-	-
Profit Before Tax	1,464	9,811	6,251	9,300	12,045
Margin (%)	2%	14%	8%	10%	12%
Total Tax	978	1,443	2,159	3,255	3,613
Effective tax rate (%)	67%	15%	35%	35%	30%
Minority Interest & Share of					
Loss from Associates	241	-5	2	3	4
Profit after tax of discontinued operations					
Profit after tax	727	8,363	4,094	6,048	8,435
EPS	4.6	52.5	25.7	38.0	53.0
YoY gr. (%)	-212%	1050%	-51%	48%	39%

Source: Company, Systematix Research

### Cash Flow

YE: Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT	1,705	9,806	6,251	9,300	12,045
Depreciation	3,819	3,686	4,443	4,857	5,728
Interest	2,723	2,403	2,114	1,952	1,979
Others	1,012	-3,908	-1,083	-717	-796
Working capital	2,531	1,118	-8,126	-1,084	-1,227
Direct tax	-2,077	-2,384	-2,159	-3,255	-3,613
<b>Net cash from Op. activities</b>	<b>9,713</b>	<b>10,721</b>	<b>1,440</b>	<b>11,053</b>	<b>14,116</b>
Net Capital expenditures	-8,977	-11,156	-13,147	-9,632	10,039
Others	2,898	16,033	628	717	796
<b>Net Cash from Invt. activities -6,079</b>	<b>4,877</b>	<b>-12,519</b>	<b>-8,915</b>	<b>10,835</b>	
Issue of share cap. / premium	-274	-47	-	-	-
Debt changes	-3,253	225	7,372	344	390
Dividend paid	-798	-796	-	-	-
Others	-	-2,356	-2,230	-2,521	-2,546
<b>Net cash from Fin. activities -4,325</b>	<b>-2,974</b>	<b>5,141</b>	<b>-2,177</b>	<b>-2,156</b>	
Effect of exchange rate changes	116	248	-	-	-
<b>Net change in cash</b>	<b>-575</b>	<b>12,872</b>	<b>-5,938</b>	<b>-39</b>	<b>22,795</b>

Source: Company, Systematix Research

### Balance Sheet

YE: Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	158	158	158	158	158
Reserves & Surplus	54,181	62,391	65,910	71,383	79,243
Minority Interest	-128	-163	-161	-158	-154
<b>Net Worth</b>	<b>54,211</b>	<b>62,386</b>	<b>65,907</b>	<b>71,383</b>	<b>79,247</b>
Short term debt	2,470	2,866	3,038	3,381	3,772
Long term debt	31,671	21,503	24,503	24,503	24,503
Trade payables	8,563	10,048	10,107	11,281	12,546
Other Provisions	1,665	1,975	2,349	2,475	2,629
Other liabilities	16,905	28,786	31,352	32,039	32,880
<b>Total Liabilities</b>	<b>1,15,485</b>	<b>1,27,564</b>	<b>1,37,254</b>	<b>1,45,062</b>	<b>1,55,576</b>
Net block	56,650	57,700	60,404	69,559	76,934
CWIP	12,523	27,147	33,147	28,768	5,625
Other Non-current asset	9,568	7,185	7,185	7,185	7,185
Investments	422	435	435	435	435
Cash and Cash Equivalents	9,568	10,888	4,950	4,911	27,706
Debtors	9,159	8,915	11,166	12,382	13,869
Inventories	12,896	11,292	15,957	17,811	19,808
Other current asset	4,699	4,002	4,010	4,012	4,014
<b>Total Assets</b>	<b>1,15,485</b>	<b>1,27,564</b>	<b>1,37,254</b>	<b>1,45,062</b>	<b>1,55,576</b>

Source: Company, Systematix Research

### Key Financial Metrics

YE: Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
<b>Per Share(Rs)</b>					
EPS	4.6	52.5	25.7	38.0	53.0
CEPS	28.5	75.6	53.6	68.5	88.9
BVPS	340.3	391.7	413.8	448.2	497.5
DPS	5.0	3.0	3.0	3.0	3.0
Return Ratio(%)					
RoCE	6.6	10.4	10.0	11.5	15.2
RoE	0.9	14.4	6.4	8.8	11.2
Balance Sheet					
Net Debt : Equity (x)	0.5	0.2	0.3	0.3	0.01
Net Working Capital (Days)	136	90	94	124	124
Valuation(x)					
PER	240.6	20.9	42.7	28.9	20.7
EV/EBITDA	22.1	16.0	15.6	12.9	9.3
EV/Sales	3.0	2.6	2.4	2.2	1.7
Receivables (days)	51	46	45	47	47
Inventory (days)	228	191	188	208	209
Payables (days)	143	147	139	132	132

Source: Company, Systematix Research

## DISCLOSURES/APPENDIX

## I. ANALYST CERTIFICATION

I, **Vishal Manchanda, Loveleen Bagga, CA; Virti Shah**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

## I. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

## STOCK RATINGS

**BUY (B):** The stock's total return is expected to exceed 15% over the next 12 months.

**HOLD (H):** The stock's total return is expected to be within -15% to +15% over the next 12 months.

**SELL (S):** The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

**NOT RATED (NR):** The analyst has no recommendation on the stock under review.

## INDUSTRY VIEWS

**ATTRACTIVE (AT):** Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

**NEUTRAL (NL):** Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

**CAUTIOUS (CS):** Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

## II. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

**SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.**

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.



#### Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051  
Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: [www.systematixgroup.in](http://www.systematixgroup.in)

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840